Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Phase 2 study of tabalumab, a human anti-B-cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma.

Raje NS, Moreau P, Terpos E, Benboubker L, Grząśko N, Holstein SA, Oriol A, Huang SY, Beksac M, Kuliczkowski K, Tai DF, Wooldridge JE, Conti I, Kaiser CJ, Nguyen TS, Cronier DM, Palumbo A.

Br J Haematol. 2017 Mar;176(5):783-795. doi: 10.1111/bjh.14483. Epub 2016 Dec 22.

PMID:
28005265
2.

A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), as Monotherapy and in Combination with Erlotinib in Advanced Cancer.

Rosen LS, Goldman JW, Algazi AP, Turner PK, Moser B, Hu T, Wang XA, Tuttle J, Wacheck V, Wooldridge JE, Banck M.

Clin Cancer Res. 2017 Apr 15;23(8):1910-1919. doi: 10.1158/1078-0432.CCR-16-1418. Epub 2016 Oct 10.

3.

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.

Raje NS, Faber EA Jr, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC.

Clin Cancer Res. 2016 Dec 1;22(23):5688-5695. Epub 2016 Jun 10.

4.

Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.

Nash Smyth E, Conti I, Wooldridge JE, Bowman L, Li L, Nelson DR, Ball DE.

J Med Econ. 2016;19(5):477-86. doi: 10.3111/13696998.2015.1132225. Epub 2016 Jan 22.

PMID:
26671598
5.

Phase 1/2 study of ocaratuzumab, an Fc-engineered humanized anti-CD20 monoclonal antibody, in low-affinity FcγRIIIa patients with previously treated follicular lymphoma.

Ganjoo KN, de Vos S, Pohlman BL, Flinn IW, Forero-Torres A, Enas NH, Cronier DM, Dang NH, Foon KA, Carpenter SP, Slapak CA, Link BK, Smith MR, Mapara MY, Wooldridge JE.

Leuk Lymphoma. 2015 Jan;56(1):42-8. doi: 10.3109/10428194.2014.911859. Epub 2014 Jul 14.

PMID:
24717109
6.

A multicenter phase II study of single-agent enzastaurin in previously treated multiple myeloma.

Jourdan E, Leblond V, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Wooldridge JE, Moreau P.

Leuk Lymphoma. 2014 Sep;55(9):2013-7. doi: 10.3109/10428194.2013.861066. Epub 2014 May 2.

PMID:
24180331
7.

A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia.

Ghobrial IM, Moreau P, Harris B, Poon T, Jourdan E, Maisonneuve H, Benhadji KA, Hossain AM, Nguyen TS, Wooldridge JE, Leblond V.

Clin Cancer Res. 2012 Sep 15;18(18):5043-50. doi: 10.1158/1078-0432.CCR-12-0181. Epub 2012 Aug 9.

8.

Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcγRIIIa-genotyped patients with previously treated follicular lymphoma.

Forero-Torres A, de Vos S, Pohlman BL, Pashkevich M, Cronier DM, Dang NH, Carpenter SP, Allan BW, Nelson JG, Slapak CA, Smith MR, Link BK, Wooldridge JE, Ganjoo KN.

Clin Cancer Res. 2012 Mar 1;18(5):1395-403. doi: 10.1158/1078-0432.CCR-11-0850. Epub 2012 Jan 5.

9.

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia.

Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, Shanafelt TD, Bowen DA, Kay NE, Witzig TE, Weiner GJ.

Leuk Lymphoma. 2012 Feb;53(2):211-7. doi: 10.3109/10428194.2011.608451. Epub 2011 Sep 19.

10.

Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma.

Karmali R, Larson ML, Wooldridge JE, Gregory SA, O'Brien T, Shammo JM, Bueschel K, Venugopal P.

Leuk Lymphoma. 2011 Nov;52(11):2097-104. doi: 10.3109/10428194.2011.589549. Epub 2011 Jun 24.

PMID:
21702643
11.

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.

Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R.

Am J Hematol. 2011 Jul;86(7):573-8. doi: 10.1002/ajh.22048. Epub 2011 May 31.

12.

Phase I study of LY2469298, an Fc-engineered humanized anti-CD20 antibody, in patients with relapsed or refractory follicular lymphoma.

Tobinai K, Ogura M, Kobayashi Y, Uchida T, Watanabe T, Oyama T, Maruyama D, Suzuki T, Mori M, Kasai M, Cronier D, Wooldridge JE, Koshiji M.

Cancer Sci. 2011 Feb;102(2):432-8. doi: 10.1111/j.1349-7006.2010.01809.x. Epub 2011 Jan 12.

13.

Large-scale analysis of DNA methylation in chronic lymphocytic leukemia.

Rahmatpanah FB, Carstens S, Hooshmand SI, Welsh EC, Sjahputera O, Taylor KH, Bennett LB, Shi H, Davis JW, Arthur GL, Shanafelt TD, Kay NE, Wooldridge JE, Caldwell CW.

Epigenomics. 2009 Oct;1(1):39-61. doi: 10.2217/epi.09.10.

14.

Can a positive positron emission tomography scan be positive news?

Wooldridge JE.

Leuk Lymphoma. 2007 Feb;48(2):227-8. No abstract available.

PMID:
17325881
15.

Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.

Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, Rasmussen WL, Krieg AM, Weiner GJ.

J Immunother. 2006 Sep-Oct;29(5):558-68.

PMID:
16971811
16.

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

Bowles JA, Wang SY, Link BK, Allan B, Beuerlein G, Campbell MA, Marquis D, Ondek B, Wooldridge JE, Smith BJ, Breitmeyer JB, Weiner GJ.

Blood. 2006 Oct 15;108(8):2648-54. Epub 2006 Jul 6.

17.

B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation.

Jahrsdörfer B, Blackwell SE, Wooldridge JE, Huang J, Andreski MW, Jacobus LS, Taylor CM, Weiner GJ.

Blood. 2006 Oct 15;108(8):2712-9. Epub 2006 Jun 29.

18.

Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.

Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, Caldwell CW.

Carcinogenesis. 2007 Jan;28(1):60-70. Epub 2006 Jun 14.

PMID:
16774933
19.
20.

Primary cardiac non-Hodgkin's lymphoma diagnosed by transthoracic echocardiography.

Konety SH, Wooldridge JE, Kerber RE.

Echocardiography. 2006 Feb;23(2):147-8.

PMID:
16445735
21.

Improved survival of follicular lymphoma patients in the United States.

Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK.

J Clin Oncol. 2005 Aug 1;23(22):5019-26. Epub 2005 Jun 27.

PMID:
15983392
22.

Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

Juweid ME, Wiseman GA, Vose JM, Ritchie JM, Menda Y, Wooldridge JE, Mottaghy FM, Rohren EM, Blumstein NM, Stolpen A, Link BK, Reske SN, Graham MM, Cheson BD.

J Clin Oncol. 2005 Jul 20;23(21):4652-61. Epub 2005 Apr 18.

PMID:
15837965
23.

Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia.

Jahrsdörfer B, Blackwell SE, Wooldridge JE, Taylor CM, Weiner GJ.

Oligonucleotides. 2005 Spring;15(1):51-9.

PMID:
15788900
24.

Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity.

Jahrsdörfer B, Wooldridge JE, Blackwell SE, Taylor CM, Link BK, Weiner GJ.

Leukemia. 2005 May;19(5):759-66.

PMID:
15759034
25.

Optic neuropathy due to anaplastic large cell lymphoma.

Howard JG, Lee AG, Garwood M, Link BK, Wooldridge JE, Kirby P.

Semin Ophthalmol. 2004 Sep-Dec;19(3-4):81-7.

PMID:
15590542
26.

Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.

Jahrsdörfer B, Wooldridge JE, Blackwell SE, Taylor CM, Griffith TS, Link BK, Weiner GJ.

J Leukoc Biol. 2005 Mar;77(3):378-87. Epub 2004 Dec 6.

PMID:
15582984
27.

CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response.

Wooldridge JE, Weiner GJ.

Curr Opin Oncol. 2003 Nov;15(6):440-5. Review.

PMID:
14624226
28.

Post-treatment surveillance of patients with lymphoma treated with curative intent.

Wooldridge JE, Link BK.

Semin Oncol. 2003 Jun;30(3):375-81. Review.

PMID:
12870139
29.

Corticosteroids in advanced cancer.

Wooldridge JE, Anderson CM, Perry MC.

Oncology (Williston Park). 2001 Feb;15(2):225-34; discussion 234-6. Review.

30.
31.

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization.

Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM.

Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10833-7.

32.

Supplemental Content

Loading ...
Support Center